EB 1089

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes
   KC Olson, PM Kulling La, R Signorelli, CE Hamele, TL Olson, MR Conaway, DJ Feith, TP Loughran
   Cytokine, 2018;111(0):551-562.
2. VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells.
   Solomon J, Heitzer M, Liu T, Beumer J, Parise R, Normolle D, Leach D, Buchanan G, DeFranco D
   Mol Cancer Res, 2014;12(8):1166-80.
3. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death.
   Hoyer-Hansen et al.
   Cell Death Differ., 2005;12:1297
4. Vitamin D₃ analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57.
   Lu et al.
   Mol.Cancer Ther., 2008;7:1268
5. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.
   Bhatia et al.
   Mol.Cancer Ther., 2009;8:1787
6. Reversal of hypercalcaemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
   Abdaimi et al.
   Cancer Res,, 1999;59:3325
7. The calci. analogue EB1089 impairs alveolarization and induces localized regions of increased fibroblast density in neonatal rat lung.
   Ormerod et al.
   Exp.Lung.Rs., 2008;34:155
8. A vitamin D receptor agonist converts CD4+ T cells to Foxp3+ regulatory T cells in patients with ulcerative colitis.
   Dong Lu, Bin Lan, Zonren Din, Hang Chen, Guoqiang Chen
   Oncotarget, 2017;0(0):1949-2553.

Product Datasheets